MBBS (MLMC), MD (SNMC)
Ex : Senior Resident (AIIMS) , Registrar (PGIMS)
Incharge of Disease Management Group
(GI, GU, lymphoma, NHL, Myeloma, Paediatric and chest tumours /cancer / malignancies )
We report the feasibility and treatment outcomes of image-guided Three-Dimensional Conformal arc Radiation Therapy,(3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for localized prostate cancer.
Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were treated with in-room CT-guided 3D-CART . Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
TA total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median prescribed 3D-CRT dose was 82 Gy (2 Gy/fraction, dose range: 78–86 Gy), and 193 of the patients additionally received hormonal therapy. The 5-year overall survival rate was 93.9 %. Among low-, intermediate-, and high-risk patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 %, respectively. Rates of grade 2–3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 %, respectively. No patient experienced late grade 4 or higher toxicity.book appointment